Vitamin D is being touted as an anti-infective agent and it has even been suggested that vitamin D supplementation could be effective against the H1N1 influenza virus. The claims are largely based on the ability of vitamin D to induce antibacterial peptides and evidence that the immune system produces active vitamin D 
Introduction
Recently, there has been a great deal of interest in the role that vitamin D might play in host resistance to infection. The increase in attention came largely as a result of reports of two findings: (1) the immune system could produce the enzyme that converts circulating vitamin D to active vitamin D, and (2) active vitamin D produced in the immune system led to the induction of cathelicidin, which in turn inhibited replication of Mycobacterium tuberculosis in vitro. 1 This finding has then led to a number of claims being reported in the scientific and non-scientific communities that claim vitamin D as a broadly anti-infective agent. Two recent letters to the editor suggest that vitamin D supplementation would be beneficial in people infected with influenza. 2, 3 In fact, the title of one of them is 'Pandemic influenza A (H1N1): Mandatory vitamin D supplementation?' 3 Here we will review the evidence behind the claims that vitamin D status could affect the course of infection. We will first look at the evidence that in vivo the immune system produces the vitamin D 1a-hydroxylase, then briefly discuss the described roles of vitamin D in the control of innate and adaptive T-cell immunity and then end with a look at the evidence that vitamin D affects in vitro and in vivo clearance of selected infections, including M. tuberculosis and influenza. We conclude that at present the evidence does not support a positive or negative role for vitamin D in host resistance to infection.
Extra-renal production of the vitamin D 1a-hydroxylase
In 1970 Fraser and Kodicek 4 first described the kidney as the source of the vitamin D 1a-hydroxylase enzyme (Cyp27B1 gene). The data demonstrated that intact chickens produced but nephrectomized chickens failed to produce what was determined to be 1,25(OH) 2 D 3 . 4 Later it was shown by two different groups that patients with advanced renal failure or nephrectomy ( prior to transplantation) had no detectable 1,25(OH) 2 D 3 in the blood. 5, 6 Experiments in rats using radiolabeled 25(OH)D 3 (to increase the sensitivity of the assay) showed that normal, otherwise healthy nephrectomized rats failed to produce 1,25(OH) 2 D 3 in the blood, bone or intestine. 7 -9 The exception was found in nephrectomized pregnant female rats where extra-renal production of 1,25(OH) 2 D 3 was detected in the blood. 7 More recently, transgenic mice that express the bacterial LacZ reporter gene in the place of the vitamin D 1a-hydroxylase confirmed the renal-only expression. 10 No reporter gene activity was detected in skin, lung, intestine, skeletal muscle, liver and ovary. 10 Consistent with the earlier finding in rats, expression was found in the placenta of pregnant females. 10 Conversely, measurements by several groups done by mRNA expression and polyclonal antibody staining of tissues have shown 1a-hydroxylase expression in healthy tissues including the skin, lymph node and colon of both humans and mice. 11 -14 Unlike conversion of 25(OH)D 3 to 1,25(OH) 2 D 3 , these techniques fail to measure enzymatic activity, which is the most reliable measure of the vitamin D 1a-hydroxylase enzyme. Therefore, we conclude that under normal physiological conditions, animals and humans (with the exception of pregnant females) express the vitamin D 1a-hydroxylase only in the kidneys.
The question of whether extra-renal production of the 1a-hydroxylase occurs during disease, however, is still open. Several different reports suggest that during granulomatous diseases in humans, hypercalcemia can exist and may be a result of extra-renal production of 1,25(OH) 2 D 3 . 11,15 -17 The most convincing example of extra-renal production of the 1a-hydroxylase is a single anephric patient with sarcoidosis that had hypercalcemia. 15 The source of the 1,25(OH) 2 D 3 production was linked to lung macrophages isolated from several sarcoidosis patients with hypercalcemia. 18, 19 It was also shown that macrophages from other lung diseases did not produce 1a-hydroxylase activity. 20 A number of research groups have reported 1a-hydroxylase activity in vitro from cultured cells. Data from some of these in vitro systems have shown that 25(OH)D 3 is converted in vitro to 1,25(OH) 2 D 3 by monocytes and dendritic cells (DCs). 12, 21 In particular, human macrophages have been shown to produce the 1a-hydroxylase when infected with M. tuberculosis and stimulated through toll-like receptors (TLRs 1 ). However, there are no credible examples of 1a-hydroxylase production in vivo from experimental animals. There are reports in mice with experimental colitis that 1a-hydroxylase is induced, but the experiment was done using the same polyclonal antiserum that stained a variety of tissues from normal mice and humans described above. 13 The lack of confirmatory data in vivo in experimental animals may be due to differences between humans and rodents, lack of vigorous investigation in animals, or perhaps a lack of understanding of the conditions under which the 1a-hydroxylase is induced in the immune system in vivo.
Reports of extra-renal production of the 1a-hydroxylase in the immune system have led investigators to propose a role for this enzyme in situ as a source of 1,25(OH) 2 D 3 for use by the immune system. 22 However, in sarcoidosis and other granulomatous diseases the more severe disease phenotypes were associated with increased levels of 1,25(OH) 2 D 3 in the serum, and resolution of the disease following immunosuppressive therapy resulted in the correction of 1,25(OH) 2 D 3 and calcium concentrations. 16, 17, 23 The autocrine production of 1,25(OH) 2 D 3 may not be beneficial; instead, it might be that immune production of 1,25(OH) 2 D 3 is part of the pathogenic process in granulomatous diseases. More information is needed to determine under what conditions the 1a-hydroxylase enzyme is expressed in extra-renal tissues in vivo and whether or not expression of this enzyme is a positive or negative contributor to granulomatous diseases in humans.
1,25(OH) 2 D 3 suppresses Th1/Th17-mediated immunity Vitamin D has been shown by several investigators using many different systems to suppress the generation of a Th1 response both in vitro and in vivo.
24 -28 1,25(OH) 2 D 3 acts directly on T-cells to inhibit T-cell proliferation and IFN-g production. 29, 30 In addition to the direct effects of 1,25(OH) 2 D 3 on T-cells, indirect effects of 1,25(OH) 2 D 3 acting on the antigenpresenting cells (APC) also results in decreased Th1 responses. 29 1,25(OH) 2 D 3 has been recognized as an immunosuppressive agent that ameliorates the pathogenesis of several different experimental models of Th1 autoimmune diseases, including inflammatory bowel disease (IBD), diabetes, multiple sclerosis (MS), arthritis and several others (reviewed in ref. 24 ). Furthermore, vitamin D deficiency and vitamin D receptor (VDR) deficiency in mice have been shown to exacerbate experimental IBD, MS, and diabetes (reviewed in ref. 24 ). More recently, in addition to Th1 cells, many of the autoimmune disease models have been shown to depend in part on Th17 cells, which make IL-17. There are reports that treatment of naïve CD4 T-cells during Th17 priming with 1,25(OH) 2 D 3 inhibits IL-17 production. 31 In addition, 1,25(OH) 2 D 3 indirectly suppressed Th17 cell induction by inhibiting DC production of IL-6 and IL-23 that induce Th17 cells. 32 In vivo, oral 1,25(OH) 2 D 3 treatment reversed Th17-mediated experimental autoimmune uveitis in mice. 31 The evidence from multiple investigators using several different in vitro and in vivo systems supports both direct and indirect effects of vitamin D that inhibit Th1 and Th17 responses. direct effects on the T reg cells and indirect effects via the induction of tolerogenic DCs that promote T reg function to alleviate autoimmune disease. 33 In the gut specialized regulatory T-cells that express the CD8aa homodimer protect the gastrointestinal tract from bacterial microflora and other antigens found there. VDR knockout (KO) mice have reduced numbers of CD8aa T-cells and are more susceptible to several different models of experimental IBD. 34 Vitamin D is required for the development of CD8aa T-cells, and in the gut reduced IL-10 production by the CD8aa T-cells is associated with increased experimental IBD in the VDR KO mice. 34 
Effect of vitamin D on Th2 immune responses
Th2-mediated immune responses are also regulated by vitamin D. Two studies showed that 1,25(OH) 2 D 3 increased the production of IL-4 and IL-10 by CD4þ T-cells under Th2 cell culture conditions in vitro. 36, 37 Conversely, it has also been reported that addition of 1,25(OH) 2 D 3 inhibits the production of IL-4 in Th2 cells and does not affect the expression of genes important in Th2 differentiation. 38 In vivo experiments in the Th2-mediated disease experimental allergic asthma also provide conflicting results. Using the ovalbumin/alum model of experimental allergic asthma, 1,25(OH) 2 D 3 has been shown to inhibit, induce or to have no effect on symptoms of experimental asthma. 39 -41 VDR KO mice failed to develop allergic asthma, while vitamin D deficiency had no effect in the same model. 
Vitamin D and innate immunity
The innate immune system plays an important role in early defense and antigen presentation. Regulation of macrophage and DC function by 1,25(OH) 2 D 3 is important for the inhibition of experimental autoimmunity. 1,25(OH) 2 D 3 treatment of DCs in vitro inhibited differentiation and maturation of DC and resulted in DCs that when transferred, induced in vivo suppression of alloreactive T-cells. 42 1,25(OH) 2 D 3 -treated DCs produced lower levels of IL-12, and expressed less co-stimulatory and MHC class II molecules than control-treated DCs. 48 Stimulation through TLRs in the presence of vitamin D inhibits inflammatory cytokine production (IL-12, TNF-a and IL-1b) in cells of the innate immune system while enhancing several antimicrobial pathways.
Evidence for a role of vitamin D in infectious immunity
Our current understanding of the effects of vitamin D on immune function can be used to predict the effects of vitamin D on host immunity to infectious organisms. The same Th1/Th17 immune responses that are pathogenic in autoimmunity are protective during infections. In addition, regulatory T-cells not only suppress autoimmune diseases, but also suppress clearance of infectious organisms. Based on the ability of vitamin D to suppress innate and acquired immune responses that result in the suppression of Th1-and Th17-mediated immune responses, we would predict that vitamin D would impair the ability of the host to clear infections dependent on these cell types. Furthermore, vitamin D would be predicted to increase T reg cells that would suppress responses to infectious organisms. However, the ability of vitamin D to induce antibacterial peptides suggests a less straightforward outcome of changes in vitamin D in vivo and resultant effects on host resistance to infection.
The experimental data that has looked at the relationship between vitamin D and infections has been summarized in Table 1 . Listeria monocytogenes is a food-borne pathogen that has commonly been used to study the Th1-mediated immune response to intracellular bacterial infections. Helming et al. 49 showed that treating IFN-g-activated macrophages with 1,25(OH) 2 D 3 inhibits listeriacidal activity and suppressed oxidative burst. In vitro, VDR KO macrophages were as good as wild-type (WT) for killing Listeria. 49 In vivo, VDR KO mice produced more IFN-g but showed slightly delayed kinetics in Listeria clearance compared with WT. 50 However, VDR KO mice were able to clear Listeria infections. 50 1,25(OH) 2 D 3 treatment of WT mice had no effect on the rate of Listeria clearance in vivo (unpublished data). Clearance of Leishmania major is also dependent on Th1-mediated responses and 1,25(OH) 2 D 3 -treated macrophages produced less nitric oxide and killed fewer parasites. 51 Infection of VDR KO mice with L. major showed normal Th1 responses and clearance of the organisms. 51 Vitamin D-deficient mice were more susceptible to Mycobacterium bovis infection than vitamin D-sufficient mice. 52 The increased susceptibility of vitamin D-deficient mice to M. bovis infection was linked to an effect on nitric oxide production. 52 1,25(OH) 2 D 3 treatment did not alter the ability of mice to clear two infections that require Th1/Th17-mediated immunity (Candida albicans or herpes simplex virus-1 53 ). Host resistance to Shistosoma mansoni requires a strong Th2-mediated response. VDR KO mice had larger liver granulomas (Th2-mediated), but were no different from wild-type mice in their ability to clear a S. mansoni infection. 54 In addition, 1,25(OH) 2 D 3 treatment had no effect on the S. mansoni infection (unpublished data). Host immunity to Bordetella pertusis infection requires Th1 and Th2 responses and VDR KO mice were no different than WT mice in their ability to clear B. pertusis infection (unpublished data). The evidence in mice does not support either a beneficial or harmful effect of vitamin D on host immunity to infections that require either Th1/Th17-or Th2-mediated immune responses for clearance. Epidemiological data suggest that low vitamin D status is associated with TB severity or susceptibility. 63 Often mentioned is the anecdotal association that patients placed in the sun would see improvement in TB symptoms. A meta-analysis showed a positive association between VDR polymorphisms and host susceptibility to TB. 63 Recently, a double-blind, randomized and placebo-controlled trial used three high dose (100,000 IU) vitamin D supplements in TB patients. 64 The study showed no beneficial effect in clinical outcome or mortality in TB. 64 Another recent report in dialysis patients showed no correlation between vitamin D supplementation and decreased risk of TB infection. 65 Thus far, the evidence in humans with TB does not support a beneficial or harmful role of vitamin D supplementation.
Vitamin D, tuberculosis and influenza
It is estimated that at least one upper respiratory tract infection (URI) afflicts 72% of adults each year. 66 The effect of vitamin D on URI is based on epidemiological data and therefore associations. 25(OH)D 3 levels have been inversely associated with URI incidence. 66 In a randomized, double-blind trial of vitamin D supplementation, vitamin D was shown to have no effect on the clinical course of URIs. 67 In 2006 Cannell et al. 68 suggested that children who received vitamin D supplements had a decreased incidence of respiratory infections and attributed this observation to vitamin D regulation of the antimicrobial peptides Decreased infection: ; increased infection: ; no effect: NE cathelicidin and defensin b2. Vitamin D has been shown to increase the expression of antibacterial peptides; however, the effect of vitamin D on these antibacterial peptides in vitro or in vivo against influenza has not been tested. Leikina et al. 69 showed that retrocyclin (not shown to be a vitamin D target), a theta-defensin (that is not expressed by humans), can inhibit influenza virus in a canine-derived cell line. Any effect of either vitamin D or 1,25(OH) 2 D 3 on influenza replication in vitro and/or in vivo has so far not been tested.
Conclusions
At present, there is not adequate information available to claim vitamin D as an anti-infective agent. The data supporting vitamin D as a factor that could improve resistance to infection are based on in vitro experiments that demonstrate immune cells make the vitamin D 1a-hydroxylase, and that 1,25(OH) 2 Author contributions: All authors participated in the design, interpretation and writing of the review. We thank Dr Avery August and the members of the Center for Immunology and Infectious Diseases for lively discussions.
